JP2022502508A - 抗cd30抗体薬物複合体療法を使用して末梢性t細胞リンパ腫を処置する方法 - Google Patents

抗cd30抗体薬物複合体療法を使用して末梢性t細胞リンパ腫を処置する方法 Download PDF

Info

Publication number
JP2022502508A
JP2022502508A JP2021542087A JP2021542087A JP2022502508A JP 2022502508 A JP2022502508 A JP 2022502508A JP 2021542087 A JP2021542087 A JP 2021542087A JP 2021542087 A JP2021542087 A JP 2021542087A JP 2022502508 A JP2022502508 A JP 2022502508A
Authority
JP
Japan
Prior art keywords
antibody
ptcl
cell lymphoma
lymphoma
drug conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502508A5 (cg-RX-API-DMAC7.html
Inventor
マンリー,トーマス
ジョセフソン,ニール
Original Assignee
シージェン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シージェン・インコーポレーテッド filed Critical シージェン・インコーポレーテッド
Publication of JP2022502508A publication Critical patent/JP2022502508A/ja
Publication of JP2022502508A5 publication Critical patent/JP2022502508A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021542087A 2018-10-01 2019-10-01 抗cd30抗体薬物複合体療法を使用して末梢性t細胞リンパ腫を処置する方法 Pending JP2022502508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739631P 2018-10-01 2018-10-01
US62/739,631 2018-10-01
PCT/US2019/054107 WO2020072519A1 (en) 2018-10-01 2019-10-01 Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy

Publications (2)

Publication Number Publication Date
JP2022502508A true JP2022502508A (ja) 2022-01-11
JP2022502508A5 JP2022502508A5 (cg-RX-API-DMAC7.html) 2022-10-11

Family

ID=68296746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542087A Pending JP2022502508A (ja) 2018-10-01 2019-10-01 抗cd30抗体薬物複合体療法を使用して末梢性t細胞リンパ腫を処置する方法

Country Status (11)

Country Link
US (1) US20200102399A1 (cg-RX-API-DMAC7.html)
EP (1) EP3860658A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022502508A (cg-RX-API-DMAC7.html)
KR (1) KR20210069679A (cg-RX-API-DMAC7.html)
CN (1) CN113613678A (cg-RX-API-DMAC7.html)
AU (1) AU2019355875A1 (cg-RX-API-DMAC7.html)
CA (1) CA3114922A1 (cg-RX-API-DMAC7.html)
IL (1) IL281920A (cg-RX-API-DMAC7.html)
MX (1) MX2021003734A (cg-RX-API-DMAC7.html)
SG (1) SG11202103342QA (cg-RX-API-DMAC7.html)
WO (1) WO2020072519A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI920652B (zh) 2018-06-07 2026-04-01 美商思進公司 喜樹鹼結合物
KR20230023650A (ko) * 2020-05-13 2023-02-17 씨젠 인크. 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법
CN116964098A (zh) 2021-03-01 2023-10-27 南特生物公司 抗cd30单克隆抗体和嵌合抗原受体
WO2024145637A2 (en) * 2022-12-30 2024-07-04 The Regents Of The University Of Colorado, A Body Corporate Immunotoxin-based targeted therapy for cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089890A1 (en) * 2016-11-14 2018-05-17 Millennium Pharmaceuticals, Inc. Non-adult human dosing of anti-cd30 antibody-drug conjugates

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
EP0582595A1 (en) 1991-04-26 1994-02-16 Surface Active Limited Novel antibodies, and methods for their use
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
WO2010081004A1 (en) 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
KR20200080274A (ko) * 2017-11-01 2020-07-06 시애틀 지네틱스, 인크. 항-cd30 항체 약물 컨쥬게이트 요법의 부작용을 감소시키는 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018089890A1 (en) * 2016-11-14 2018-05-17 Millennium Pharmaceuticals, Inc. Non-adult human dosing of anti-cd30 antibody-drug conjugates

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY, vol. Vol.25, Supplement 4, JPN6023038885, 2014, pages 984, ISSN: 0005158893 *
BLOOD, vol. 120, no. 21, JPN6023038874, 2012, pages 60, ISSN: 0005360634 *
BLOOD, vol. 122, no. 21, JPN6023038876, 2013, pages 4386, ISSN: 0005360635 *
BLOOD, vol. 126, no. 23, JPN6023038881, 2015, pages 1537, ISSN: 0005158890 *
BLOOD, vol. 128, no. 22, JPN6023038882, 2016, pages 2993, ISSN: 0005158891 *
BLOOD, vol. Vol.130, Suppl_1, JPN6023038884, 2017, pages 2790, ISSN: 0005158892 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 28, JPN6023038873, 2014, pages 3137 - 3143, ISSN: 0005360633 *
NATURE BIOTECHNOLOGY, vol. 21, no. 7, JPN6023038880, 2003, pages 778 - 784, ISSN: 0005360637 *
癌と化学療法, vol. 42, no. 5, JPN6023038877, 2015, pages 550 - 552, ISSN: 0005360636 *

Also Published As

Publication number Publication date
KR20210069679A (ko) 2021-06-11
IL281920A (en) 2021-05-31
WO2020072519A8 (en) 2020-05-14
CN113613678A (zh) 2021-11-05
EP3860658A1 (en) 2021-08-11
SG11202103342QA (en) 2021-04-29
CA3114922A1 (en) 2020-04-09
US20200102399A1 (en) 2020-04-02
WO2020072519A1 (en) 2020-04-09
MX2021003734A (es) 2021-07-16
AU2019355875A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
JP7003036B2 (ja) グリコシル化pd-1に対して特異的な抗体およびその使用方法
JP2024174883A (ja) 結核菌(Mycobacterium Tuberculosis)感染の診断および治療のための新規な抗-LAMおよび抗-PIM6/LAMモノクローナル抗体
JP6611709B2 (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−4d阻害分子の使用
AU2012314390B2 (en) Anti-ICAM-1 antibodies to treat multiple-myeloma related disorders
KR20200119834A (ko) 항-cd47 및 항-cd20 항체를 이용한 항암 섭생
HK1252272A1 (zh) 使用抗ox40抗体治疗癌症的方法
TW201840335A (zh) 抗-il-23抗體
TW201509431A (zh) 人化axl抗體類
JP2010512407A (ja) 新生物を処置するための組成物および方法
TW201520226A (zh) 泛-elr+cxc趨化因子抗體
US20210246219A1 (en) Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
JP2023154026A (ja) 抗cd30抗体薬物複合体療法の副作用を軽減する方法
CN113613678A (zh) 使用抗cd30抗体药物缀合物疗法治疗外周t细胞淋巴瘤的方法
TW202017943A (zh) Cd226促效劑抗體
AU2017347822A1 (en) Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody
TW202228788A (zh) 以結合191p4d12蛋白之抗體藥物結合物(adc)治療癌症之方法
JP2024511358A (ja) PDGFRα阻害剤でがんを治療する方法
JP2022513405A (ja) 抗cd123免疫複合体を用いた治療法
JP2021535110A (ja) 併用療法
TW202345895A (zh) 在用於治療瀰漫性大型b細胞淋巴瘤之組合療法中針對cd3和cd20之雙特異性抗體
CN117651565A (zh) 抗叶酸受体偶联物与贝伐珠单抗的联合治疗
JP2022543378A (ja) Il-38特異的抗体
JP2022549495A (ja) 造血器がんの治療のための抗cd30 adc、抗pd-1、および化学療法剤の併用
RU2838203C2 (ru) Способы лечения множественной миеломы
JP2019505516A (ja) インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241224